Cardurion Pharmaceuticals, Inc. is a clinical-stage biotechnology company headquartered in Burlington, Massachusetts, focused on discovering and developing novel therapeutics for cardiovascular diseases.
Subscribe to see Cardurion Pharmaceuticals, LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Cardurion Pharmaceuticals, LLC is a therapeutics company headquartered in Burlington, United States. It has raised at least $431.7M across the 5 funding rounds on record. Its most recent funding round, Series B, raised $260.4M in July 2024. Xcout tracks 13 named people at Cardurion Pharmaceuticals, LLC, including Peter S. Lawrence (President and CEO).
As of 16 November 2026. Source: Xcout Intel.
7 more named people on record for Cardurion Pharmaceuticals, LLC, with roles, board committees and tenure — see the full roster →
At least $431.7M raised across the 5 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $260.4M | 12 named | |
| SEC Form D filing | $17.5M | — | |
| SEC Form D filing | $128.1M | — | |
| SEC Form D filing | $10M | — | |
| SEC Form D filing | $15.7M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Cardurion Pharmaceuticals, LLC's closest competitors — see the full list of competitors and alternatives →
Imbria Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing novel cardiovascular therapies.
Nocion Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Watertown, Massachusetts, focused on developing novel therapeutics to treat chronic cough and other conditions.
Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders. The company was established on December 23, 2024, and its main corporate offices are located in Burlington, Massachusetts.
Allorion Therapeutics is a US-based organization headquartered in Natick, Massachusetts, with additional operations in China, specializing in the discovery and creation of small molecule drugs using a science- and data-driven R&D strategy.
Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Falls Church, Virginia, focused on optimizing blood pressure and cardiovascular health.
Cyclerion Therapeutics, Inc. operates as a biopharmaceutical company in the clinical development phase, concentrating on the discovery, advancement, and commercialization of therapeutic agents for debilitating central nervous system (CNS) disorders. Their leading experimental compound, CY6463, is a soluble guanylate cyclase (sGC) stimulator designed to cross the blood-brain barrier. It is presently in Phase IIa clinical assessments for managing mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), as well as Alzheimer's disease with vascular involvement. Concurrently, CY6463 is undergoing Phase 1 trials for treating schizophrenia in adult populations. The company's research portfolio also features other promising candidates: Praliciguat, an orally administered systemic sGC stimulator, is in Phase II studies targeting resistant hypertension and diabetic nephropathy. Olinciguat, another sGC stimulator designed for oral intake with a vascular focus, is progressing through Phase II trials for sickle cell disease. Moreover, CY3018 is under development to address a range of CNS ailments. Cyclerion holds a licensing agreement with Akebia Therapeutics, Inc., covering the entire lifecycle from development and manufacturing to medical affairs and commercialization for certain pharmaceutical compounds and related products. The company was founded in 2018 and has its principal place of business in Cambridge, Massachusetts.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Cardurion Pharmaceuticals, LLC? Suggest a correction · Work at Cardurion Pharmaceuticals, LLC? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.